TP53 and cancer: Through the analysis of clinical data of LAC patients, the expression of PD-L1 in tumours in the TP53/KRAS comutation group was increased, and the proportion of CD8 + T cells in TME was higher, which was consistent with the clinical benefit of TP53, KRAS or TP53/KRAS-mutated cancer patients after treatment with PD-1 inhibitors113.